Nutriband FY27 Q2 net loss narrows 56% to $880,561; revenue falls 29.71% to $437,514

• Nutriband posted a Q2 net loss of USD 880,561, narrowing 55.98% from USD 2 million a year earlier.
• Revenue fell 29.71% to USD 437,514, reflecting weaker Pocono Pharmaceuticals sales after a key customer shifted operations to Asia.
• Operating loss narrowed 55.55% to USD 890,637 as selling, general and administrative expense dropped 53.03% to USD 750,317.
• Research and development expense declined 42.73% to USD 322,194, primarily on lower labor costs tied to Aversa Fentanyl development.
• Cash and cash equivalents totaled USD 3.42 million at July 31, 2026, down from USD 4.57 million at Jan. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-097701), on September 04, 2026, and is solely responsible for the information contained therein.